{"product_id":"the-future-of-bariatric-surgery-research-a-worldwide-map-of-upcoming-clinical-trials","title":"The Future of Bariatric Surgery Research: A Worldwide Map of Upcoming Clinical Trials","description":"\u003cp\u003eResearchers systematically mapped all upcoming randomized controlled trials (RCTs) in bariatric (weight-loss) surgery registered on ClinicalTrials.gov as of June 2021, identifying 62 trials involving an estimated 10,800 patients. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most-studied procedures, and obesity-related diseases—especially type 2 diabetes—have overtaken weight loss as the most common focus of investigation. However, more than half of the trials follow patients for only one year or less, which experts say is too short for a lifelong condition like obesity. The findings highlight a dynamic research field with emerging surgical techniques and a growing global footprint, while also pointing to important gaps in long-term follow-up and mental health research.\u003c\/p\u003e\n\n\u003ch1\u003eThe Future of Bariatric Surgery Research: A Worldwide Map of Upcoming Clinical Trials\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What the Research Revealed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Couldn't Tell Us\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: A Roadmap for Future Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA 2021 registry review found 62 upcoming randomized bariatric surgery trials planning about 10,800 participants.\u003c\/li\u003e\n\u003cli\u003eSleeve gastrectomy and Roux-en-Y gastric bypass were each studied in 39 trials, the most of any procedure.\u003c\/li\u003e\n\u003cli\u003eObesity-related diseases, especially type 2 diabetes, are now the most frequent focus, appearing in over 80% of trials.\u003c\/li\u003e\n\u003cli\u003eMore than half of the upcoming trials follow patients for one year or less; only 23% exceed four years.\u003c\/li\u003e\n\u003cli\u003eResearchers recommend longer follow-up and more research on nutritional deficiencies, muscle loss, and mental health after surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eObesity has grown to pandemic proportions worldwide since the early 1980s, with \u003cstrong\u003emore than 2 billion people\u003c\/strong\u003e now affected. Among the available treatment options, bariatric surgery (weight-loss surgery) remains one of the most effective treatments for patients with severe obesity who are committed to lifelong nutritional follow-up. Studies have shown that bariatric surgery leads to an increase in life expectancy, making it a cornerstone of care for carefully selected patients.\u003c\/p\u003e\n\n\u003cp\u003eThe history of bariatric surgery dates back to \u003cstrong\u003e1950\u003c\/strong\u003e, and since then, hundreds of papers have been published on the topic. Some surgical techniques have stood the test of time, while others have been abandoned. At the same time, innovative procedures are continually being developed, such as \u003cstrong\u003esleeve gastrectomy with transit bipartition (SG-TBP)\u003c\/strong\u003e and \u003cstrong\u003esingle anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-SG)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eTo understand the scale of this field, the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) reported in January 2021 that \u003cstrong\u003e604,223 primary bariatric procedures\u003c\/strong\u003e are performed worldwide each year, with sleeve gastrectomy remaining the most common. Current international guidelines recommend bariatric surgery for patients with a body mass index (BMI) of \u003cstrong\u003e40 kg\/m² or higher\u003c\/strong\u003e, or for those with a BMI of \u003cstrong\u003e35–40 kg\/m²\u003c\/strong\u003e who also have obesity-related health conditions.\u003c\/p\u003e\n\n\u003cp\u003eThis study was designed to answer a simple but important question: \u003cem\u003eWhat does the future of bariatric surgery research look like?\u003c\/em\u003e By mapping all upcoming randomized controlled trials, the researchers aimed to clarify which procedures, patient populations, and outcomes will shape the next generation of evidence in this rapidly evolving field.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe research team performed a systematic review of registered clinical trials in June 2021 using \u003cstrong\u003eClinicalTrials.gov\u003c\/strong\u003e, the world's largest clinical trial registry, which is maintained by the U.S. government and includes safeguards to ensure the validity of registration data.\u003c\/p\u003e\n\n\u003cp\u003eThe search used 2015 Medical Subject Headings (MeSH) from the U.S. National Library of Medicine, with the following key terms: \"bariatric surgery,\" \"adjustable gastric banding,\" \"sleeve gastrectomy,\" \"Roux Y gastric bypass,\" \"one anastomosis gastric bypass,\" \"biliopancreatic derivation with switch duodenal,\" \"duodenal switch,\" \"single loop duodeno-jejunal bypass with sleeve gastrectomy,\" \"single anastomosis duodeno-ileal bypass with sleeve gastrectomy,\" \"single anastomosis duodeno-ileal bypass with duodenal switch,\" and \"sleeve gastrectomy with transit bipartition.\"\u003c\/p\u003e\n\n\u003cp\u003eThe researchers followed the \u003cstrong\u003ePRISMA statement\u003c\/strong\u003e (a widely accepted guideline for reporting systematic reviews). They included trials that:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eHad not yet been published\u003c\/li\u003e\n  \u003cli\u003eCompared one primary bariatric surgical technique against another surgical procedure \u003cem\u003eor\u003c\/em\u003e against a medical (non-surgical) treatment\u003c\/li\u003e\n  \u003cli\u003eEnrolled adult patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere was \u003cstrong\u003eno restriction on outcomes\u003c\/strong\u003e, meaning the researchers looked at every possible endpoint the trials planned to measure. Two reviewers independently checked each study against the eligibility criteria to ensure accuracy.\u003c\/p\u003e\n\n\u003cp\u003eFor each trial, the team collected details on the comparisons, surgical interventions, geographic location, trial status, planned number of participants, and follow-up duration. They also recorded patient inclusion criteria—including age, BMI, and diabetes status—as well as every predefined primary and secondary outcome.\u003c\/p\u003e\n\n\u003cp\u003eOutcomes were classified into several categories:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEfficacy\u003c\/strong\u003e — weight loss; obesity-related diseases (including hypertension, type 2 diabetes, dyslipidemia, cardiovascular events, cancer, and effects on respiratory, renal, cardiac, liver function, and arthrosis); intermediate metabolic markers (such as glucose homeostasis, beta-cell function, insulin resistance, inflammation, hunger regulation, gut hormones, and gut microbiota); eating behavior; energy expenditure; and health costs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery and perioperative period\u003c\/strong\u003e — associated procedures, length of surgery and anesthesia, hospital stay, conversion to open surgery, pulse rate, grip force testing, oxygen saturation, painkiller use, blood loss, and early complications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMortality\u003c\/strong\u003e — at various time points after surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplications\u003c\/strong\u003e — divided into medical and surgical complications (with the Dindo–Clavien classification used for surgical complications).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTolerance\u003c\/strong\u003e — quality of life, general satisfaction, and gastrointestinal symptoms.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eData were summarized as percentages for categorical variables and as medians with interquartile ranges for continuous variables. All statistical analyses were performed using R Studio software version 3.3.2.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What the Research Revealed\u003c\/h2\u003e\n\n\u003ch3\u003eThe Search Results\u003c\/h3\u003e\n\n\u003cp\u003eThe electronic search identified \u003cstrong\u003e142 references\u003c\/strong\u003e on ClinicalTrials.gov. Of these, \u003cstrong\u003e20 were excluded\u003c\/strong\u003e because they were not randomized trials, \u003cstrong\u003e38 were duplicates\u003c\/strong\u003e, and \u003cstrong\u003e22 were excluded\u003c\/strong\u003e because the results had already been published. This left a final total of \u003cstrong\u003e62 randomized controlled trials\u003c\/strong\u003e included in the analysis.\u003c\/p\u003e\n\n\u003ch3\u003eThe Trials at a Glance\u003c\/h3\u003e\n\n\u003cp\u003eThe 62 upcoming trials plan to enroll a combined total of approximately \u003cstrong\u003e10,800 patients\u003c\/strong\u003e. The median number of patients planned per trial is \u003cstrong\u003e78\u003c\/strong\u003e (with half of all trials planning between 50 and 143 participants).\u003c\/p\u003e\n\n\u003cp\u003eTrial status varied widely:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e23 trials (37%)\u003c\/strong\u003e were actively recruiting patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e12 trials (19%)\u003c\/strong\u003e were completed but not yet published\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10 trials (16.4%)\u003c\/strong\u003e were active but not recruiting\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e8 trials (13%)\u003c\/strong\u003e were not yet recruiting\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e8 trials (13%)\u003c\/strong\u003e had an unknown status\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1 trial (1.6%)\u003c\/strong\u003e was terminated\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhich Surgical Procedures Are Being Studied\u003c\/h3\u003e\n\n\u003cp\u003eTwo procedures dominate the research landscape, each appearing in \u003cstrong\u003e39 trials (62.9% of all studies)\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSleeve gastrectomy (SG)\u003c\/strong\u003e — the most commonly performed bariatric procedure worldwide, in which roughly 80% of the stomach is removed\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRoux-en-Y gastric bypass (RYGB)\u003c\/strong\u003e — a procedure that creates a small stomach pouch and reroutes the small intestine\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOther procedures being studied include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOne anastomosis gastric bypass (OAGBP):\u003c\/strong\u003e 7 trials (11.3%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdjustable gastric banding (AGB):\u003c\/strong\u003e 5 trials (8.1%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-SG):\u003c\/strong\u003e 5 trials (8.1%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle loop duodeno-jejunal bypass with sleeve gastrectomy (SLDJBP-SG):\u003c\/strong\u003e 3 trials (4.8%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuodenal switch (DS):\u003c\/strong\u003e 3 trials (4.8%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSleeve gastrectomy with transit bipartition (SG-TBP):\u003c\/strong\u003e 2 trials (3.2%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle anastomosis duodeno-ileal bypass with duodenal switch (SADI-DS):\u003c\/strong\u003e 1 trial (1.6%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiliopancreatic derivation with duodenal switch (BPD-DS):\u003c\/strong\u003e 1 trial (1.6%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNissen sleeve gastrectomy (N-SG):\u003c\/strong\u003e 1 trial (1.6%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNotably, most trials with very long follow-up periods involve bypass-type procedures: \u003cstrong\u003e71% of OAGBP trials\u003c\/strong\u003e plan to follow patients for more than 4 years, as do \u003cstrong\u003e40% of SADI-SG trials\u003c\/strong\u003e and all of the SADI-DS, BPD-DS, and DS trials. By contrast, \u003cstrong\u003e59% of SG trials\u003c\/strong\u003e follow patients for only 0–1 year.\u003c\/p\u003e\n\n\u003ch3\u003eWhere the Trials Are Happening\u003c\/h3\u003e\n\n\u003cp\u003eHalf of all upcoming trials (31 trials, \u003cstrong\u003e50%\u003c\/strong\u003e) are planned in Europe, making it the most active region for bariatric surgery research. The geographic breakdown is as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEurope:\u003c\/strong\u003e 31 trials (50%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNorth America:\u003c\/strong\u003e 13 trials (21%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsia:\u003c\/strong\u003e 7 trials (11%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSouth America:\u003c\/strong\u003e 6 trials (9.7%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAfrica:\u003c\/strong\u003e 5 trials (8.1%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOceania:\u003c\/strong\u003e 0 trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, the emergence of bariatric surgery RCTs in Africa is a notable development, as this region was previously absent from the scientific production of randomized trials in this field.\u003c\/p\u003e\n\n\u003ch3\u003eWho Will Participate in These Trials\u003c\/h3\u003e\n\n\u003cp\u003eThe vast majority of trials (\u003cstrong\u003e94%\u003c\/strong\u003e) plan to enroll adults aged \u003cstrong\u003e18 to 70 years\u003c\/strong\u003e. Only 1 trial (1.6%) plans to include older patients aged 65–80, and 3 trials (4.8%) focus on younger adults aged 18–40\/50.\u003c\/p\u003e\n\n\u003cp\u003eRegarding BMI requirements:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e60% of trials\u003c\/strong\u003e require a BMI of at least 35 kg\/m²\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e26% of trials\u003c\/strong\u003e include patients with BMI ≥25\/30 kg\/m² (overweight to mild obesity)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4.8% of trials\u003c\/strong\u003e require BMI ≥40\/45 kg\/m²\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3.2% of trials\u003c\/strong\u003e require BMI ≥50 kg\/m² (severe obesity)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNearly a third of trials (\u003cstrong\u003e29%\u003c\/strong\u003e) focus exclusively on patients with diabetes, highlighting the close relationship between bariatric surgery and metabolic disease management.\u003c\/p\u003e\n\n\u003ch3\u003eHow Trials Are Designed: Surgery vs. Medical Treatment\u003c\/h3\u003e\n\n\u003cp\u003eMost trials (\u003cstrong\u003e63%\u003c\/strong\u003e) use another surgical procedure as the comparison group, while \u003cstrong\u003e48%\u003c\/strong\u003e compare surgery against medical (non-surgical) treatment. Some trials use both types of comparators. For example, among RYGB trials, 59% use a medical control group and 59% use a surgical control group.\u003c\/p\u003e\n\n\u003cp\u003eFollow-up duration is one of the most striking findings:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e55% of trials\u003c\/strong\u003e follow patients for 1 year or less\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e18%\u003c\/strong\u003e follow patients for 1–2 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4.8%\u003c\/strong\u003e follow patients for 2–3 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e0%\u003c\/strong\u003e follow patients for 3–4 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e23%\u003c\/strong\u003e follow patients for more than 4 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhat Outcomes Are Being Measured\u003c\/h3\u003e\n\n\u003cp\u003eThe most striking shift in bariatric surgery research is the change in focus: \u003cstrong\u003eweight loss is no longer the most commonly studied outcome\u003c\/strong\u003e. Instead, obesity-related diseases are the most frequent focus, appearing in \u003cstrong\u003e80.6% (81%) of all trials\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eAmong the obesity-related diseases studied:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eType 2 diabetes:\u003c\/strong\u003e 62.9% of trials\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDyslipidemia\u003c\/strong\u003e (abnormal blood fats): 45.2% of trials\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypertension\u003c\/strong\u003e (high blood pressure): 33.9% of trials\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRespiratory function:\u003c\/strong\u003e 21% of trials\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiver function:\u003c\/strong\u003e 17.7% of trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOther outcomes being measured across the trials include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTolerance of surgery\u003c\/strong\u003e (including quality of life, general satisfaction, and gastrointestinal symptoms): evaluated in nearly half of all trials, with \u003cstrong\u003equality of life specifically measured in 37%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgical complications\u003c\/strong\u003e — though notably, the standardized \u003cstrong\u003eDindo–Clavien classification\u003c\/strong\u003e was used in only \u003cstrong\u003e12.9%\u003c\/strong\u003e of trials\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntermediate metabolic markers\u003c\/strong\u003e (glucose control, beta-cell function, insulin resistance, inflammation, hunger-regulating hormones, gut hormones, and gut microbiota): studied in more than one-third of trials\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedical complications\u003c\/strong\u003e, including nutritional deficiencies (19.4% of trials), sarcopenia (muscle loss, 3.2%), and mental health (3.2%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMortality\u003c\/strong\u003e and \u003cstrong\u003ebody composition\u003c\/strong\u003e (changes in fat vs. muscle mass)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe growing attention to body composition is particularly important because it helps define undernutrition in recent international guidelines (such as the GLIM criteria).\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis mapping study offers patients a clear picture of what the future of bariatric surgery may hold. First, the large number of ongoing and upcoming trials reflects the \u003cstrong\u003edynamism of this surgical field\u003c\/strong\u003e and the continued commitment to refining surgical techniques.\u003c\/p\u003e\n\n\u003cp\u003eThe shift in focus from weight loss alone to \u003cstrong\u003eobesity-related diseases and metabolic health\u003c\/strong\u003e is good news for patients. It means future research is increasingly asking whether bariatric surgery can do more than help patients lose weight—it asks whether surgery can improve or even reverse conditions like type 2 diabetes, high blood pressure, abnormal cholesterol, and fatty liver disease. The rise of \"metabolic surgery\" as a concept supports this broader view of surgery as a treatment for metabolic disease, not just obesity.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the short follow-up duration of most trials is a concern. \u003cstrong\u003eMore than half of the trials (55%) plan to follow patients for only 1 year or less\u003c\/strong\u003e, and only 23% extend beyond 4 years. Since bariatric surgery is intended to treat a lifelong chronic disease, the researchers argue that short-term studies may miss important long-term outcomes—both benefits (such as sustained disease remission and improved survival) and risks (including nutritional deficiencies that may take years to develop).\u003c\/p\u003e\n\n\u003cp\u003eFor patients considering bariatric surgery, this means that some of the evidence guiding treatment decisions may be based on relatively short follow-up periods. When discussing surgery with their healthcare team, patients should ask about long-term data for the specific procedure being considered.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Couldn't Tell Us\u003c\/h2\u003e\n\n\u003cp\u003eThis study has several limitations that should be kept in mind. First, the review focused \u003cstrong\u003eonly on randomized controlled trials\u003c\/strong\u003e, which provide the highest level of evidence but represent just one part of the broader research landscape. This means the mapping provides a somewhat fragmented view of future bariatric surgery research, since observational studies, registry data, and other study designs were not included.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the researchers note that \u003cstrong\u003ethese registered trials are not guaranteed to be published in the future\u003c\/strong\u003e. Some trials may fail to recruit enough participants, encounter methodological problems, or never reach the publication stage, which could change the actual evidence landscape compared to what the registry predicts.\u003c\/p\u003e\n\n\u003cp\u003eFinally, information available in clinical trial registries can be incomplete or updated over time. The study reflects a snapshot in time (June 2021), and the status of many trials may have changed since then.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: A Roadmap for Future Research\u003c\/h2\u003e\n\n\u003cp\u003eBased on their findings, the researchers make several important recommendations for the future of bariatric surgery research:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExtend follow-up durations.\u003c\/strong\u003e Given that bariatric surgery treats a lifelong chronic disease, trials that follow patients for only a few months or a single year are insufficient. Future trials should be designed with longer follow-up periods—ideally 4 years or more—to capture the full range of benefits and risks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInvest more in under-researched areas.\u003c\/strong\u003e Nutritional deficiency risk, sarcopenia (muscle wasting), and mental health after surgery remain severely underinvestigated, with only 3.2% of trials studying the latter two. Given the potential consequences of nutritional deficiencies and the concerning rates of depressive syndrome or addiction after bariatric surgery, these areas deserve greater attention.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandardize how complications are reported.\u003c\/strong\u003e Only 12.9% of trials used the standardized Dindo–Clavien classification for surgical complications. Consistent use of validated classification systems would make it easier to compare results across studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSupport research in underrepresented regions.\u003c\/strong\u003e The emergence of trials in Africa is promising, but the global distribution of research remains uneven, with Europe and North America dominating the field. Wider geographic diversity would improve the generalizability of findings to patients worldwide.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoid research waste.\u003c\/strong\u003e By carefully considering what is already known and addressing questions that have not yet been answered, future studies can avoid duplicating existing evidence and focus resources on the most meaningful questions.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eFor patients, this roadmap reinforces the importance of asking their surgical team about the long-term evidence base for any procedure, including data on quality of life, nutritional outcomes, and mental health support after surgery.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWho is eligible for bariatric surgery based on current international guidelines?\u003c\/h3\u003e\n\u003cp\u003eCurrent guidelines recommend bariatric surgery for adults with a body mass index (BMI) of 40 kg\/m² or higher, or for those with a BMI of 35 to 40 kg\/m² who also have obesity-related health conditions. Eligibility should always be confirmed by a qualified healthcare team. The procedure requires a lifelong commitment to nutritional follow-up.\u003c\/p\u003e\n\u003ch3\u003eWhich bariatric procedures are most often studied in upcoming clinical trials?\u003c\/h3\u003e\n\u003cp\u003eSleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most-studied procedures, each appearing in 39 of the 62 upcoming randomized controlled trials. Other techniques studied include one anastomosis gastric bypass, adjustable gastric banding, and SADI-SG. These trials plan to enroll about 10,800 patients in total.\u003c\/p\u003e\n\u003ch3\u003eHow long do most upcoming bariatric surgery trials follow patients after surgery?\u003c\/h3\u003e\n\u003cp\u003eMore than half of the upcoming trials (55%) follow patients for one year or less. Only about 23% extend beyond four years. Researchers consider this too short for a lifelong condition like obesity, because important benefits and risks, such as nutritional deficiencies, may take years to appear. Patients should ask about long-term data.\u003c\/p\u003e\n\u003ch3\u003eWhat is the main focus of new bariatric surgery research?\u003c\/h3\u003e\n\u003cp\u003eObesity-related diseases have overtaken weight loss as the most common focus. Type 2 diabetes appears in 62.9% of trials, dyslipidemia in 45.2%, and hypertension in 33.9%. This shift supports the concept of metabolic surgery, meaning future research asks whether surgery can improve or reverse conditions like diabetes, not just produce weight loss.\u003c\/p\u003e\n\u003ch3\u003eWhere in the world are the upcoming bariatric surgery trials being conducted?\u003c\/h3\u003e\n\u003cp\u003eHalf of all upcoming trials (31 of 62) are planned in Europe, making it the most active region. North America accounts for 21%, Asia 11%, South America about 10%, and Africa 8%. The emergence of trials in Africa is notable because this region previously had no randomized bariatric surgery trials, according to the mapping study.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my surgical team about long-term evidence for a weight-loss procedure?\u003c\/h3\u003e\n\u003cp\u003eAsk about long-term data for the specific procedure you are considering, including follow-up beyond one year. Also ask about quality of life, nutritional outcomes, and mental health support after surgery. The researchers recommend future trials focus on nutritional deficiencies, muscle loss, and mental health because these areas remain underinvestigated in current research.\u003c\/p\u003e\n\u003ch3\u003eWhat limitations of this study should patients be aware of?\u003c\/h3\u003e\n\u003cp\u003eThe study included only randomized controlled trials, not observational studies or registries. It is a snapshot from June 2021, so trial statuses may have changed. Also, registered trials are not guaranteed to be published later; some may fail to recruit enough participants or encounter other problems. Therefore, the actual future evidence may differ from this map.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e The future of bariatric surgery research  A worldwide mapping of registered trials\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Claire Rives-Lange, Tigran Poghosyan, Nathalie Rassy, Claire Carette, Aurelie Phan, Marc Goeau-Brissonnière, Flore de Castelbajac, Amel Merazka, and Sebastien Czernichow\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Obesity Reviews, 2022;23:e13433. Published by the World Obesity Federation (Wiley).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1111\/obr.13433\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e This study was conducted without funding.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclosures:\u003c\/strong\u003e The authors declared the following potential conflicts of interest: Sebastien Czernichow received consulting fees from Novonordisk, Lilly, Fresenius Kabi, Janssen, Novartis, Servier, and Boehringer; participated on Data Safety Monitoring Boards for Bariatek and Novonordisk; and holds stock or stock options in Jellynov and Mygoodlife. Claire Carette received consulting fees from AstraZeneca, Lilly, Novartis Pharma, MSD France, IPSEN Pharma, Pfizer, and Publicis Health, and received travel support from Astra Zeneca, Novo Nordisk, Lilly, Vitalaire, and MSD France. All other authors declared no conflicts of interest.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Patients considering bariatric surgery should consult with qualified healthcare professionals.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400025260188,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com.br\/products\/the-future-of-bariatric-surgery-research-a-worldwide-map-of-upcoming-clinical-trials","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}